NPHC NUTRA PHARMA CORP
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1119643 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-49.0%
TTM net income YoY-255.0%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-1,017.8%
Net margin-3,370.6%
FCF margin—
EBITDA margin-1,011.4%
Returns
ROE—
ROA-731.5%
ROIC (approx.)—
Asset turnover0.22x
Leverage & solvency
Liabilities / assets3,505.0%
Debt / equity—
Current ratio0.02x
Interest coverage-68.24x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-589.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $34,463 | $27,246 | $28,864 | $70,242 | $84,532 | $73,974 | $81,873 | $74,994 |
| Cost of revenue | $25,297 | $29,239 | $65,973 | $34,128 | $58,715 | $46,263 | $175,672 | $23,777 |
| Gross profit | $32,625 | $18,975 | -$11,907 | $64,576 | $63,428 | $59,131 | $86,588 | $70,693 |
| SG&A expense | — | — | — | $420,652 | $366,157 | $418,150 | $265,455 | $255,445 |
| Operating income | -$435,464 | -$379,249 | -$465,914 | -$356,076 | -$290,529 | -$349,819 | -$178,867 | -$184,752 |
| Interest expense | $6,248 | $6,002 | $5,955 | $5,780 | $5,550 | $5,585 | $5,577 | $5,413 |
| Pretax income | -$3.95M | -$459,675 | -$488,526 | -$523,520 | $369,577 | -$1.40M | -$230,907 | -$260,683 |
| Net income | -$3.95M | -$459,675 | -$488,526 | -$523,520 | $369,577 | -$1.40M | -$230,907 | -$260,683 |
| EBITDA | -$433,106 | -$376,748 | -$463,342 | -$353,307 | -$287,366 | -$347,674 | -$177,007 | -$182,892 |
| EPS (basic) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 8.07B | 8.01B | — | 7.82B | 37.73B | 7.68B | — | 7.66B |
| Balance sheet | ||||||||
| Cash & equivalents | — | $21,844 | $12,181 | $3,603 | $79,069 | $13,843 | $36,447 | $0 |
| Short-term investments | $17,600 | $17,600 | $17,600 | $17,600 | $17,600 | $17,600 | $17,600 | $17,600 |
| Receivables | — | — | — | — | — | — | — | $23,149 |
| Inventory | $23,509 | $23,506 | $19,535 | $17,518 | $15,658 | $17,571 | $17,696 | $17,073 |
| Current assets | $463,119 | $499,424 | $459,583 | $545,106 | $665,128 | $552,117 | $374,837 | $310,755 |
| PP&E, net | $20,946 | $23,304 | $25,805 | $28,377 | $31,146 | $34,309 | $10,402 | $12,262 |
| Total assets | $622,863 | $616,518 | $622,601 | $709,853 | $859,068 | $775,179 | $599,495 | $558,838 |
| Current liabilities | $21.70M | $17.74M | $17.31M | $16.92M | $16.55M | $16.85M | $15.27M | $15.21M |
| Short-term debt | $12.44M | $9.87M | $9.62M | $9.54M | $9.35M | $8.92M | $8.49M | $8.29M |
| Long-term debt | $134,808 | $135,730 | $136,644 | $137,550 | $138,447 | $139,336 | $140,217 | $141,089 |
| Total debt | $12.57M | $10.01M | $9.76M | $9.67M | $9.48M | $9.06M | $8.63M | $8.43M |
| Total liabilities | $21.83M | $17.88M | $17.45M | $17.06M | $16.69M | $16.99M | $15.41M | $15.38M |
| Shareholders' equity | -$21.21M | -$17.26M | -$16.83M | -$16.35M | -$15.83M | -$16.21M | -$14.81M | -$14.82M |
| Net debt | — | $9.98M | $9.75M | $9.67M | $9.41M | $9.04M | $8.59M | $8.43M |
| Shares outstanding | 7.16B | 7.16B | 7.10B | 7.10B | 7.10B | 7.10B | 7.10B | 7.10B |
| Cash flow statement | ||||||||
| Operating cash flow | -$251,223 | -$327,791 | -$219,818 | -$250,770 | -$288,370 | -$405,006 | -$178,210 | $19,073 |
| Capital expenditure | — | — | $0 | $0 | $0 | $26,052 | — | — |
| Free cash flow | — | — | -$219,818 | -$250,770 | -$288,370 | -$431,058 | — | — |
| Investing cash flow | — | — | $0 | $0 | -$25,000 | -$26,052 | $8,300 | $34,000 |
| Financing cash flow | $229,379 | $337,454 | $228,396 | $175,304 | $378,596 | $408,454 | $206,357 | -$53,073 |
| Depreciation & amortization | $2,358 | $2,501 | $2,572 | $2,769 | $3,163 | $2,145 | $1,860 | $1,860 |
| Stock-based compensation | $3,583 | $11,250 | $16,500 | $8,500 | $1,667 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.